<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39390688</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Serum-derived bovine immunoglobulin treatment in COVID-19 is associated with faster resolution of symptoms: A randomized pilot clinical trial.</ArticleTitle><Pagination><StartPage>e70005</StartPage><MedlinePgn>e70005</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.70005</ELocationID><Abstract><AbstractText>Effective treatment to prevent hospitalization and death in people with COVID-19 exists, but people still need interventions that alleviate symptoms without drug interactions. Oral serum-derived bovine immunoglobulins (SBI) may reduce symptoms and time-to-improvement in people with mild-to-moderate COVID-19. In this randomized, open-label, single-site study, participants with mild-to-moderate COVID-19 received SBI 5.0 g bis in die (BID) + Standard of Care (SOC) or SOC alone (2:1) for 2 weeks. After 2 weeks, 78.8% of hospitalized participants on SBI + SOC improved by World Health Organization (WHO) scale of ≥3 compared to 61.1% on SOC alone (odds ratio: OR = 2.4; p = 0.0663), with older participants (&gt;57 years) showing more significant differences between the arms (OR = 6.1; p = 0.0109). Further, more participants on SBI + SOC reported absence of COVID-19 symptoms at Week 2 (74.2%) compared to SOC alone (43.6%; OR = 3.7; p = 0.0031), most notably the absence of dyspnea on exertion (OR = 4.4; p = 0.0047), with women exhibiting the most significant eradication of all symptoms (OR = 5.8; p = 0.0080). No difference in change of IL-6 between arms was observed. Overall, participants with mild-to-moderate COVID-19 on SBI + SOC had a shorter time-to-recovery than on SOC alone, with a significantly higher rate of complete resolution of symptoms. Dyspnea on exertion was the symptom most significantly impacted. For people with mild-to-moderate COVID-19, oral SBI could be a safe and effective intervention, devoid of drug interactions.</AbstractText><CopyrightInformation>© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Utay</LastName><ForeName>Netanya S</ForeName><Initials>NS</Initials><Identifier Source="ORCID">0000-0002-6407-8670</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Güerri-Fernández</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9794-9161</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases Hospital del Mar., Univ. Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gharakhanian</LastName><ForeName>Shahin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0006-6247-6911</Identifier><AffiliationInfo><Affiliation>CIC: Cambridge Innovation Center, Pharmaceutical Medicine &amp; Infectious Diseases, Shahin Gharakhanian MD Consulting LLC, One Broadway, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asmuth</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0003-0916-7950</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of California, Davis, Sacramento, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contreras</LastName><ForeName>Moises</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Proliant Health &amp; Biologicals, Ankeny, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunkler</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9319-6652</Identifier><AffiliationInfo><Affiliation>Proliant Health &amp; Biologicals, Ankeny, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Detzel</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Proliant Health &amp; Biologicals, Ankeny, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warner</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0003-4472-7503</Identifier><AffiliationInfo><Affiliation>Proliant Health &amp; Biologicals, Ankeny, Iowa, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Proliant Health &amp; Biologicals</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007136" MajorTopicYN="N">Immunoglobulins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">disease management</Keyword><Keyword MajorTopicYN="N">medical food product</Keyword><Keyword MajorTopicYN="N">serum‐derived bovine immunoglobulin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39390688</ArticleId><ArticleId IdType="doi">10.1002/jmv.70005</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497‐506. doi:10.1016/s0140-6736(20)30183-5</Citation></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061‐1069. doi:10.1001/jama.2020.1585</Citation></Reference><Reference><Citation>Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID‐19). Postgrad Med J. 2020;96(1142):753‐758. doi:10.1136/postgradmedj-2020-138234</Citation></Reference><Reference><Citation>Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty‐day outcomes among patients hospitalized with COVID‐19. Ann Intern Med. 2021;174(4):576‐578. doi:10.7326/m20-5661</Citation></Reference><Reference><Citation>Brandão SCS, Ramos JOX, Dompieri LT, et al. Is toll‐like receptor 4 involved in the severity of COVID‐19 pathology in patients with cardiometabolic comorbidities? Cytokine Growth Factor Rev. 2021;58:102‐110. doi:10.1016/j.cytogfr.2020.09.002</Citation></Reference><Reference><Citation>Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs. J Med Virol. 2020;92(10):2105‐2113. doi:10.1002/jmv.25987</Citation></Reference><Reference><Citation>Zhao Y, Kuang M, Li J, et al. SARS‐CoV‐2 spike protein interacts with and activates TLR41. Cell Res. 2021;31(7):818‐820. doi:10.1038/s41422-021-00495-9</Citation></Reference><Reference><Citation>Utay NS, Asmuth DM, Gharakhanian S, Contreras M, Warner CD, Detzel CJ. Potential use of serum‐derived bovine immunoglobulin/protein isolate for the management of COVID‐19. Drug Dev Res 2021;82(7):873‐879. doi:10.1002/ddr.21841</Citation></Reference><Reference><Citation>Lee S, Channappanavar R, Kanneganti TD. Coronaviruses: innate immunity, inflammasome activation, inflammatory cell death, and cytokines. Trends Immunol. 2020;41(12):1083‐1099. doi:10.1016/j.it.2020.10.005</Citation></Reference><Reference><Citation>Rohilla S. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus‐2 disease: COVID‐19. Drug Dev Res. 2021;82(1):12‐26. doi:10.1002/ddr.21720</Citation></Reference><Reference><Citation>Giron LB, Dweep H, Yin X, et al. Corrigendum: plasma markers of disrupted gut permeability in severe COVID‐19 patients. Front Immunol. 2021;12:779064. doi:10.3389/fimmu.2021.779064</Citation></Reference><Reference><Citation>Gu J, Han B, Wang J. COVID‐19: gastrointestinal manifestations and potential fecal‐oral transmission. Gastroenterology. 2020;158(6):1518‐1519. doi:10.1053/j.gastro.2020.02.054</Citation></Reference><Reference><Citation>NIH. COVID‐19 Treatment Guidelines Panel. Final coronavirus disease 2019 (COVID‐19) treatment guidelines. NIH. https://www.covid19treatmentguidelines.nih.gov/</Citation></Reference><Reference><Citation>Fernandes Q, Inchakalody VP, Merhi M, et al. Emerging COVID‐19 variants and their impact on SARS‐CoV‐2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54(1):524‐540. doi:10.1080/07853890.2022.2031274</Citation></Reference><Reference><Citation>Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID‐19. Viruses. 2020;12(4):372. doi:10.3390/v12040372</Citation></Reference><Reference><Citation>Andrews HS, Herman JD, Gandhi RT. Treatments for COVID‐19. Annu Rev Med. 2024;75:145‐157. doi:10.1146/annurev-med-052422-020316</Citation></Reference><Reference><Citation>Yoo SH, Kim L, Lu M, Nagoshi K, Namchuk MN. A review of clinical efficacy data supporting emergency use authorization for COVID‐19 therapeutics and lessons for future pandemics. Clin Transl Sci. 2022;15(10):2279‐2292. doi:10.1111/cts.13384</Citation></Reference><Reference><Citation>Chew KW, Malani PN, Gandhi RT. COVID‐19 therapeutics for nonhospitalized patients‐updates and future directions. JAMA. 2023;330(16):1519‐1520. doi:10.1001/jama.2023.19542</Citation></Reference><Reference><Citation>Gandhi RT, Hirsch M. Treating acute Covid‐19 ‐ final chapters still unwritten. N Engl J Med. 2024;390(13):1234‐1236. doi:10.1056/NEJMe2402224</Citation></Reference><Reference><Citation>Detzel CJ, Horgan A, Henderson AL, et al. Bovine immunoglobulin/protein isolate binds pro‐inflammatory bacterial compounds and prevents immune activation in an intestinal co‐culture model. PLoS One. 2015;10(4):e0120278. doi:10.1371/journal.pone.0120278</Citation></Reference><Reference><Citation>Horgan A, Maas K, Henderson A, Detzel C, Weaver E. Serum‐derived bovine immunoglobulin/protein isolate binds to pathogen‐associated molecular patterns. FASEB J. 2014;28:836.6.</Citation></Reference><Reference><Citation>Utay NS, Somasunderam A, Hinkle JE, et al. Serum bovine immunoglobulins improve inflammation and gut barrier function in persons with HIV and enteropathy on suppressive ART. Pathog and Immun. 2019;4(1):124‐146. doi:10.20411/pai.v4i1.276</Citation></Reference><Reference><Citation>Van den Abbeele P, Detzel C, Rose A, Deyaert S, Baudot A, Warner C. Serum‐derived bovine immunoglobulin stimulates SCFA production by specific microbes in the ex vivo SIFR(®) technology. Microorganisms 2023;11(3):659. doi:10.3390/microorganisms11030659</Citation></Reference><Reference><Citation>Shaw AL, Mathews DW, Hinkle JE, et al. Absorption and safety of serum‐derived bovine immunoglobulin/protein isolate in healthy adults. Clin Exp Gastroenterol. 2016;9:365‐375. doi:10.2147/ceg.S120118</Citation></Reference><Reference><Citation>Asmuth DM, Hinkle JE, LaMarca A, et al. Evaluation of oral serum‐derived bovine immunoglobulins in HIV‐infected patients with chronic idiopathic diarrhea. HIV Clin Trials. 2017;18(5‐6):205‐213. doi:10.1080/15284336.2017.1401256</Citation></Reference><Reference><Citation>Asmuth DM, Ma ZM, Albanese A, et al. Oral serum‐derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. AIDS. 2013;27(14):2207‐2217. doi:10.1097/QAD.0b013e328362e54c</Citation></Reference><Reference><Citation>Stotts MJ, Cheung A, Hammami MB, et al. Evaluation of serum‐derived bovine immunoglobulin protein isolate in subjects with decompensated cirrhosis with ascites. Cureus. 2021;13(6):e15403. doi:10.7759/cureus.15403</Citation></Reference><Reference><Citation>Petschow BW. Bovine immunoglobulin protein isolates for the nutritional management of enteropathy. World J Gastroenterol. 2014;20(33):11713‐11726. doi:10.3748/wjg.v20.i33.11713</Citation></Reference><Reference><Citation>Petschow BW, Burnett BP, Shaw AL, Weaver EM, Klein GL. Dietary requirement for serum‐derived bovine immunoglobulins in the clinical management of patients with enteropathy. Dig Dis Sci. 2015;60(1):13‐23. doi:10.1007/s10620-014-3322-0</Citation></Reference><Reference><Citation>Wilson D, Evans M, Weaver E, Shaw AL, Klein GL. Evaluation of serum‐derived bovine immunoglobulin protein isolate in subjects with diarrhea‐predominant irritable bowel syndrome. Clin Med Insights Gastroenterol. 2013;6:CGast.S13200. doi:10.4137/CGast.S13200</Citation></Reference><Reference><Citation>Shafran I, Burgunder P, Wei D, Young HE, Klein G, Burnett BP. Management of inflammatory bowel disease with oral serum‐derived bovine immunoglobulin. Therap Adv Gastroenterol. 2015;8(6):331‐339. doi:10.1177/1756283x15593693</Citation></Reference><Reference><Citation>Arthington JD, Jaynes CA, Tyler HD, Kapil S, Quigley JD. The use of bovine serum protein as an oral support therapy following coronavirus challenge in calves. J Dairy Sci. 2002;85(5):1249‐1254. doi:10.3168/jds.S0022-0302(02)74189-1</Citation></Reference><Reference><Citation>Lorca IGG, Campbell J. Potential positive effect of commercial spray‐dried porcine plasma on pigs challenged with PRRS virus. Presented at: Proceedings of the 21st International Pig Veterinary Society; 2010. International Pig Veterinary Society.</Citation></Reference><Reference><Citation>Abani O, Abbas A, Abbas F, et al. Tocilizumab in patients admitted to hospital with COVID‐19 (RECOVERY): a randomised, controlled, open‐label, platform trial. The Lancet. 2021;397(10285):1637‐1645. doi:10.1016/s0140-6736(21)00676-0</Citation></Reference><Reference><Citation>Gordon AC, Mouncey PR, Al‐Beidh F, et al. Interleukin‐6 receptor antagonists in critically ill patients with Covid‐19. N Engl J Med. 2021;384(16):1491‐1502. doi:10.1056/NEJMoa2100433</Citation></Reference><Reference><Citation>Rose AOA, Warner C. Bovine immunoglobulin/protein isolate binds to SARS‐CoV‐2 spike protein and disrupts binding to ACE2. Presented at: World Microbe Forum; 2021. Online Worldwide.</Citation></Reference><Reference><Citation>Nguyen VOA, Warner C. Serum‐derived Bovine Immunoglobulin/Protein Isolate Inhibits TMPRSS2 Proteolysis of SARS‐CoV2 Spike Protein S2’ Domain. presented at: World Microbe Forum. Online Worldwide; 2021.</Citation></Reference><Reference><Citation>World Health Organization. WHO R&amp;D blueprint: Novel coronovirus COVID‐19 therapeutic trial synopsis. World Health Organization. https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis</Citation></Reference><Reference><Citation>Advarra. Retention in clinical trials: Keeping patients on protocols. Advarra; 2024. https://www.advarra.com/resource-library/retention-in-clinical-trials-keeping-patients-on-protocols/</Citation></Reference><Reference><Citation>de Brabander J, Michels EHA, van Linge CCA, et al. Association between dexamethasone treatment and the host response in COVID‐19 patients admitted to the general ward. Respir Res. 2022;23(1):145. doi:10.1186/s12931-022-02060-3</Citation></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72,314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239‐1242. doi:10.1001/jama.2020.2648</Citation></Reference><Reference><Citation>Goda GS, Soltas EJ. The impacts of covid‐19 absences on workers. J Public Econ. 2023;222:104889. doi:10.1016/j.jpubeco.2023.104889</Citation></Reference><Reference><Citation>Pocock SJ, Stone GW. The primary outcome fails—what next? N Engl J Med. 2016;375(9):861‐870. doi:10.1056/NEJMra1510064</Citation></Reference><Reference><Citation>Liu B, Jayasundara D, Pye V, et al. Whole of population‐based cohort study of recovery time from COVID‐19 in New South Wales Australia. Lancet Reg Health West Pac. 2021;12:100193. doi:10.1016/j.lanwpc.2021.100193</Citation></Reference><Reference><Citation>Rea IM, Alexander HD. Triple jeopardy in ageing: COVID‐19, co‐morbidities and inflamm‐ageing. Ageing Res Rev. 2022;73:101494. doi:10.1016/j.arr.2021.101494</Citation></Reference><Reference><Citation>GlobalHealth5050. The COVID‐19 Sex‐Disaggregated Data Tracker. GlobalHealth5050. https://globalhealth5050.org/the-sex-gender-and-covid-19-project/the-data-tracker/</Citation></Reference><Reference><Citation>Promislow DEL. A geroscience perspective on COVID‐19 mortality. J Gerontol A Biol Sci Med Sci. 2020;75(9):30. doi:10.1093/gerona/glaa094</Citation></Reference><Reference><Citation>Luck AN, Elo IT, Preston SH, Paglino E, Hempstead K, Stokes AC. COVID‐19 and all‐cause mortality by race, ethnicity, and age across five periods of the pandemic in the United States. Popul Res Policy Rev 2023;42(4):71. doi:10.1007/s11113-023-09817-8</Citation></Reference><Reference><Citation>Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir‐;ritonavir in preventing hospital admissions and deaths in people with COVID‐19: a cohort study in a large US health‐care system. Lancet Infect Dis. 2023;23(7):806‐815. doi:10.1016/S1473-3099(23)00118-4</Citation></Reference><Reference><Citation>Entera Health. EnteraGam package insert. Entera Health. https://enteragam.com/healthcare-professionals/full-product-information/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>